Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy

• Published in: American journal of clinical dermatology Vol. 21; no. 5; pp. 749 - 751
• Main Authors: Piaserico, Stefano, Gisondi, Paolo, Cazzaniga, Simone, Naldi, Luigi
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2020; Springer Nature B.V
• Subjects: Adult; Aged; Betacoronavirus; Biological Therapy - adverse effects; Cohort Studies; Coronavirus Infections - epidemiology; Coronavirus Infections - etiology; Coronaviruses; COVID-19; Dermatology; Female; Humans; Italy - epidemiology; Letter to the Editor; Male; Medicine; Medicine & Public Health; Middle Aged; Pandemics; Pharmacology/Toxicology; Pharmacotherapy; Pneumonia, Viral - epidemiology; Pneumonia, Viral - etiology; Psoriasis - drug therapy; SARS-CoV-2; TNF inhibitors; Tumor Necrosis Factor Inhibitors - adverse effects; Tumor necrosis factor-TNF; Young Adult; Italy
• ISSN: 1175-0561; 1179-1888
• DOI: 10.1007/s40257-020-00552-w

All of these conditions have been associated with a significantly increased rate of hospitalization and fatal course in COVID-19 patients [5]. [...]a higher incidence of COVID-19-related hospitalization and death would have been expected in our psoriasis patients. [...]some preliminary data on TNF inhibitors and IL-12/23 inhibitors in inflammatory bowel disease patients showed that these therapies do not worsen the clinical course of COVID-19 compared with sulfasalazine/ mesalamine [6]. In our study, however, we focus on the Veneto Region where one of the first Italian outbreaks of COVID occurred. [...]we extended the follow-up time to 1 June, 2020.